ALESSANDRA FERRAJOLI to Risk Assessment
This is a "connection" page, showing publications ALESSANDRA FERRAJOLI has written about Risk Assessment.
Connection Strength
0.215
-
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832.
Score: 0.063
-
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center. Cancer. 2013 Sep 01; 119(17):3177-85.
Score: 0.046
-
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.
Score: 0.019
-
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncol. 2019 11; 20(11):1576-1586.
Score: 0.018
-
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
Score: 0.015
-
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer. 2017 Sep 01; 123(17):3367-3376.
Score: 0.015
-
Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches. Crit Rev Oncol Hematol. 1996 Apr; 22(3):151-74.
Score: 0.014
-
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95.
Score: 0.010
-
Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol. 2010 Nov; 23(11):1518-23.
Score: 0.009
-
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):581-9.
Score: 0.006